Zobrazeno 1 - 10
of 41
pro vyhledávání: '"Steven E. Vogl"'
Autor:
Steven E. Vogl
Publikováno v:
Breast cancer research and treatment. 166(1)
Currently available data supporting adjuvant ovarian function suppression for resected breast cancer in premenopausal women in addition to standard chemotherapy and tamoxifen are not persuasive, even though an ASCO guideline supports them. Available
Autor:
Steven E. Vogl
Publikováno v:
Journal of Clinical Oncology. 36:624-625
Autor:
Steven E Vogl
Publikováno v:
The Lancet Oncology. 17:e125-e126
Autor:
Dirk F. Moore, Martin M. Oken, Selina M. Luger, Steven E. Vogl, John M. Bennett, John H. Glick, Jules E. Harris, Peter H. Wiernik
Publikováno v:
Leukemia & Lymphoma. 30:601-607
Mitoguazone, an investigational agent with significant activity in advanced lymphoma, was added to a modified CHOP regimen (COPA) in an effort to improve the activity of standard therapy in 66 previously untreated patients with stages II-IV lymphoma
Publikováno v:
American Journal of Clinical Oncology. 21:565-567
High-dose megestrol acetate has been reported to be effective salvage therapy for women with ovarian carcinoma. The Eastern Cooperative Oncology Group performed this phase II study of oral megestrol acetate, 200 mg four times daily until disease prog
Publikováno v:
Cancer. 67:681-683
A 45-year-old man was diagnosed with multiple myeloma, IgA-kappa, in 1975. Thirteen years later he presented with obstructive jaundice. Computed tomography (CT) showed a 6-cm mass in the head of the pancreas. Needle aspiration showed myeloma. The jau
Autor:
Liting Zhu, Paul E. Goss, Judy-Anne W. Chapman, Lois E. Shepherd, Steven E. Vogl, Abdullah Altwairgi
Publikováno v:
Journal of Clinical Oncology. 30:e11005-e11005
e11005 Background: MA.27 examined the efficacy of 5 yrs of adjuvant aromatase inhibitors (AI), exemestane and anastrozole. Long term outcomes of AI trials may be influenced by unspecified subsequent hormonal therapy so we enquired about its frequency
Autor:
Barry H. Kaplan, Eugene Fazzini, T. E. Davis, Geoffrey Falkson, Brigitte Cheuvart, Beow Y. Yeap, Robert L. Comis, Peter H. Wiernik, Steven E. Vogl, John Horton
Publikováno v:
Cancer investigation. 10(1)
A total of 248 analyzable patients with Stages III-IV ovarian epithelial cancer (114 with and 134 without prior chemotherapy) were randomized to one of four cisplatin (DDP)-hexamethylmelamine (HMM) regimens. In each, HMM, 200 mg/m2 was given orally d
Autor:
Dennis L. Citrin, John C. Marsh, Donald L. Trump, Steven E. Vogl, Richard G. Hahn, Larry K. Kvols, T. E. Davis
Publikováno v:
Investigational new drugs. 8
Twenty-nine patients with metastatic prostate cancer progressing after hormonal therapy (orchiectomy 19, diethylstilbestrol 10) and who had never received cytotoxic therapy were treated with carboplatin. Patients had good clinical performance status
Autor:
John Horton, Harvey J. Lerner, Barry H. Kaplan, Richard H. Creech, Steven E. Vogl, Leon Barnes, David A. Schoenfeld
Publikováno v:
Cancer. 50:2295-2300
Patients with advanced, incurable squamous cancer of the head and neck were randomly assigned to treatment with weekly methotrexate alone or methotrexate with Corynebacterium parvum given subcutaneously in weekly bilateral doses in sites around the n